未知生产厂商
CAStem is composed of immunity- and matrix-regulatory cells (IMRCs), also known as M cells, which can be administered through injection. These IMRCs are differentiated from human embryonic stem cells that are expanded and then harvested. These cells are currently being investigated against lung injury and fibrosis -- conditions which are outcomes of lung disorders including COVID-19. IMRCs are similar to MSCs in terms of their capacity for self-renewal and tri-lineage differentiation. However, the difference comes with IMRCs displaying a higher quality of consistency, having stronger immunomodulatory and anti-fibrotic functions, and being stronger in potential treatment of lung injury and fibrosis.
CAStem is composed of immunity- and matrix-regulatory cells (IMRCs), also known as M cells, which can be administered through injection. These IMRCs are differentiated from human embryonic stem cells that are expanded and then harvested. These cells are currently being investigated against lung injury and fibrosis -- conditions which are outcomes of lung disorders including COVID-19. IMRCs are similar to MSCs in terms of their capacity for self-renewal and tri-lineage differentiation. However, the difference comes with IMRCs displaying a higher quality of consistency, having stronger immunomodulatory and anti-fibrotic functions, and being stronger in potential treatment of lung injury and fibrosis.
IMRCs are different from cells such as the umbilical cord mesenchymal stem cells in gene expression profile; thus, this results in IMRCs possessing qualities such as higher expression levels of proliferative, immunomodulatory, and anti-fibrotic genes. Additionally, they have the ability to modulate immunity and regulate extracellular matrix production.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
